Page 290 - 2021_02-Haematologica-web

604
Letters to the Editor
Ludek Pour,14 Martin Stork,4 Lubica Harvanova,15
Martin Mistrik,15 Gabor Mikala,16 Pawel Robak,17
Anna Czyz,16 Jakub Debski,18 Lidia Usnarska-Zubkiewicz,18 Artur Jurczyszyn,19 Lukas Stejskal,20 Gareth Morgan,21 Fedor Kryukov,1,2°° Eva Budinska,6 Michal Simicek,1,2,4 Tomas Jelinek,1,2,4 Matous Hrdinka1,2,4 and Roman Hajek1,2
1Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic; 2Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic; 3LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 4Department of Biology and Ecology, Faculty of Science, University of Ostrava, Ostrava, Czech Republic; 5Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Olomouc, Czech Republic; 6RECETOX, Faculty of Science, Masaryk university in Brno, Brno, Czech Republic; 7Brno University of Technology, Faculty of Information Technology, Center of Excellence IT4Innovations, Brno, Czech Republic; 8Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic; 9Department of Hematology and Cancer Prevention, Facility of Health Sciences, Medical University of Silesia in Katowice, Poland; 10Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland; 11Charles University Hospital Pilsen, Pilsen, Czech Republic; 12Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK; 13IT4Innovations, VŠB – Technical University of Ostrava, Ostrava, Czech Republic; 14Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic; 15Department of Hematology and Transfusiology, Faculty of Medicine Comenius University, University Hospital Bratislava, Bratislava, Slovakia; 16Department of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Budapest, Hungary; 17Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Łódž, Poland; 18Department and Clinic of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland; 19Jagiellonian University Medical College, Cracow, Poland; 20Silesian Hospital Opava, Opava, Czech Republic and 21Department of Medicine, Multiple Myeloma Research Perlmutter Cancer Center, NYU School of Medicine, New York, NY, USA
*ZC and TS contributed equally as co-first authors
°current address: Biomedical Center, Faculty of Medicine, Charles University of Pilsen, Pilsen & Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czech Republic
°°current address: JSC “BIOCAD” Company, Saint-Petersburg, Russia
Correspondence: ROMAN HAJEK - roman.hajek@osu.cz doi:10.3324/haematol.2019.239756
Disclosures: no conflicts of interests to disclose.
Contributions: ZC and TS contributed equally to this manuscript , processed nucleic acid samples, designed experiments, prepared the figures and wrote the manuscript; PV, JP, LB, EB, AM and MMo performed bioinformatic and statistical analysis; KG, JF and MZ
performed cell sorting and nucleic acid isolation; TJ, LP, MS, SG, WWJ, AWG, AJ, AB, MH, LH, MMi, GM, PR, JD, AJ, JS and AC diagnosed patients, collected samples of peripheral blood and bone marrow and provided patient’s clinical data; GM provided the multiple myeloma exome data; FK designed the study and organized the initial sample collection and experiments; RH designed the study and managed the team; MS, MH and TJ designed experiments and
wrote the manuscript. All authors have commented on and proofread the manuscript.
Acknowledgments: we thank the anonymous reviewers for their valuable comments on the manuscript. We thank the Biobank in Brno and Ostrava for providing the archived samples of bone marrow and peripheral blood. We thank Mgr. Lucie Cerna for help with cell sorting and nucleic acid isolation. We are grateful to Shira Timilsina, MD for English language editing.
Funding: this work was supported by the Ministry of Health of the Czech Republic (15-29667A).
References
1. Merlini G, Palladini G. Light chain amyloidosis: the heart of the prob- lem. Haematologica. 2013;98(10):1492-1495.
2. Desikan KR, Dhodapkar MV, Hough A, et al. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplan- tation. Leuk Lymphoma. 1997;27(3–4):315-319.
3. Jelinek T, Kryukova E, Kufova Z, Kryukov F, Hajek R. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clin- ical activity. Hematol Oncol. 2017;35(4):408-419.
4. Jelinek T, Kufova Z, Hajek R. Immunomodulatory drugs in AL amy- loidosis. Crit Rev Oncol Hematol. 2016;99:249-260.
5. Babayan A, Alawi M, Gormley M, et al. Comparative study of whole genome amplification and next generation sequencing per- formance of single cancer cells. Oncotarget. 2016;8(34):56066-56080.
6. Itan Y, Shang L, Boisson B, Patin E, et al. The human gene damage index as a gene-level approach to prioritizing exome variants. Proc Natl Acad Sci U S A. 2015;112(44):13615-13620.
7. Bolli N, Biancon G, Moarii M, et al. Analysis of the genomic land- scape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018;32(12):2604-2616.
8. Boyle EM, Ashby C, Wardell CP, et al. The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood. 2018; 132(26):2775-2777.
9. Paiva B, Martinez-Lopez J, Corchete LA, et al. Phenotypic, transcrip- tomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood. 2016;127(24):3035-3039.
10. Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015; 33(33):3911-3920.
11. Kryukov F, Kryukova E, Brozova L, et al. Does AL amyloidosis have a unique genomic profile? Gene expression profiling meta-analysis and literature overview. Gene. 2016;591(2):490-498.
12. Crawford DR, Wang Y, Schools GP, Kochheiser J, Davies KJ. Down- regulation of mammalian mitochondrial RNAs during oxidative stress. Free Radic Biol Med. 1997;1;22(3):551-559.
13. Oliva L, Orfanelli U, Resnati M, et al. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor tox- icity. Blood. 2017;129(15):2132-2142.
14. Bochtler T, Merz M, Hielscher T, et al. Cytogenetic intraclonal het- erogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Adv. 2018;2(20):2607-2618.
haematologica | 2021; 106(2)